Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis

JAMA Psychiatry

Volumn 73, Issue 3, 2016, Pages 199-210

  Samara, Myrto T ^a   Dold, Markus ^b   Gianatsi, Myrsini ^c   Nikolakopoulou, Adriani ^c   Helfer, Bartosz ^a   Salanti, Georgia ^d   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE;

DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROGRAM ACCEPTABILITY; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; THERAPEUTIC EQUIVALENCE; TREATMENT RESISTANT SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; ADULT; BAYES THEOREM; DOUBLE BLIND PROCEDURE; DRUG RESISTANCE; FEMALE; MALE; MIDDLE AGED; PATIENT ATTITUDE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BAYES THEOREM; BENZODIAZEPINES; CLOZAPINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84962512924     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.2955     Document Type: Review

References (106)

1. Hasan A, Falkai P,Wobrock T, et al;World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.World J Biol Psychiatry. 2012;13(5):318-378.
2. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620.
3. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2)(suppl):1-56.
4. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
5. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull. 1988;24(1):62-67.
6. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9): 789-796.
7. Buchanan RW, Breier A, Kirkpatrick B, Ball P, CarpenterWT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155(6):751-760.
8. Rosenheck R, Cramer J, XuW, et al; Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337(12):809-815.
9. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158(4): 518-526.
10. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999;156(7):990-999.
11. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009; (1):CD000059.
12. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatmentsmeta-analysis. Lancet. 2013; 382(9896):951-962.
13. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(11):CD006633.
14. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: ameta-analysis. Lancet. 2009;373 (9657):31-41.
15. Davis JM, Chen N, Glick ID. Ameta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564.
16. McEvoy JP, Lieberman JA, Stroup TS, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610.
17. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUTLASS 1). Arch Gen Psychiatry. 2006;63(10): 1079-1087.
18. Higgins JP,Welton NJ. Networkmeta-analysis: a norm for comparative effectiveness? Lancet. 2015;386(9994):628-630.
19. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130-137.
20. Leucht S, Komossa K, Rummel-Kluge C, et al. Ameta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2): 152-163.
21. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials:methodological issues. Int J Epidemiol. 2002;31(1):140-149.
22. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. J Gen Intern Med. 1992;7(6):623-629.
23. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Chichester, England: Wiley & Sons; 2011.
24. Bian ZX, Li YP, Moher D, et al. Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology. Zhong Xi Yi Jie He Xue Bao. 2006;4 (2):120-129.
25. Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials. 2009;10:46.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
27. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
28. GuyW. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville,MD: US Dept of Health, Education, andWelfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218-222.DHEW Publication ADM 76-338.
29. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res. 2008;98(1-3): 318-322.
30. Leucht S, Kane JM, Etschel E, KisslingW, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology. 2006;31(10):2318-2325.
31. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007;32(9):1903-1910.
32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
33. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331(7521):897-900.
34. Dias S, Sutton AJ,Ades AE,WeltonNJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and networkmeta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5): 607-617.
35. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325-337.
36. Higgins JP, Green S, Scholten RJ. Maintaining reviews: updates, amendments and feedback. In: Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons Ltd; 2008:31-49.
37. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2): 163-171.
38. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80-97.
39. Jansen JP, Naci H. Is networkmeta-analysis as valid as standard pairwisemeta-analysis? it all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.
40. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013;8(10): e76654.
41. Dias S,Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641-656.
42. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472.
43. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42(1):332-345.
44. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in networkmeta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2): 98-110.
45. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for networkmeta-analysis with random inconsistency effects. Stat Med. 2014;33(21):3639-3654.
46. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2): 111-125.
47. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693.
48. Leucht S, SamaraM, Heres S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dosemethod. Schizophr Bull. 2015;41(6):1397-1402.
49. Leucht S, SamaraM, Heres S, Patel MX,Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: theminimum effective dose method. Schizophr Bull. 2014;40(2): 314-326.
50. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3(2):161-176.
51. Kane JM, Meltzer HY, Carson WH Jr,McQuade RD, Marcus RN, Sanchez R; Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68(2):213-223.
52. Howard JS III. Haloperidol for chronically hospitalized psychotics: a double-blind comparison with thiothixene and placebo: a follow-up open evaluation. Dis Nerv Syst. 1974;35(10):458-463.
53. Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther. 1984;1(2):77-97.
54. Hall WB, Vestre ND, Schiele BC, Zimmermann R. A controlled comparison of haloperidol and fluphenazine in chronic treatment-resistant schizophrenics. Dis Nerv Syst. 1968;29(6):405-408.
55. Browne FWA, Cooper SJ,Wilson R, King DJ. Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients. J Psychopharmacol. 1988;2(2):94-103.
56. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158(8):1305-1313.
57. Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol. 1997;12(3):123-130.
58. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58(10):965-972.
59. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255-262.
60. Bitter I, Dossenbach MR, Brook S, et al; Olanzapine HGCK Study Group. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28 (1):173-180.
61. Conley RR, Kelly DL, Richardson CM, Tamminga CA, CarpenterWT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23(6):668-671.
62. Meltzer HY, BoboWV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274-285.
63. Moresco RM, Cavallaro R, Messa C, et al. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004;18(3):355-365.
64. Naber D, Riedel M, Klimke A, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005;111(2):106-115.
65. Tollefson GD, BirkettMA, Kiesler GM,Wood AJ; Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001; 49(1):52-63.
66. Bondolfi G, Dufour H, Patris M, et al; Risperidone Study Group. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry. 1998;155(4):499-504.
67. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999; 156(2):294-298.
68. McGurk SR, Carter C, Goldman R, et al. The effects of clozapine and risperidone on spatial working memory in schizophrenia. Am J Psychiatry. 2005;162(5):1013-1016.
69. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimon R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24(6):911-922.
70. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B,Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study [published correction appears in Schizophr Res. 2010;121(1-3)281]. Schizophr Res. 2009;113(1):112-121.
71. Altamura AC, Velona I, Curreli R, Mundo E, Bravi D. Is olanzapine better than haloperidol in resistant schizophrenia? a double-blind study in partial responders. Int J Psychiatry Clin Pract. 2002;6(2): 107-111.
72. AstraZeneca Clinical Trials. A multicentre, double-blind, randomised comparison of quetiapine (Seroquel) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia. 5077IL/0031. http://www .astrazenecaclinicaltrials.com/Submission/View?id =988. Verified November 2013. Accessed March 14, 2014.
73. AstraZeneca Clinical Trials. A multicentre, double-blind, randomised trial to compare the effects of seroquel and chlorpromazine in patients with treatment resistant schizophrenia [TRESS]. 5077IL/0054. http://www.astrazenecaclinicaltrials .com/Submission/View?id=994. Verified November 2013. Accessed March 14, 0214.
74. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999;45(4):403-411.
75. Buchanan RW, BallMP,Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry. 2005;162(1): 124-129.
76. Chen JJ, Chan HY, Chen CH, Gau SS, Hwu HG. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. Pharmacopsychiatry. 2012;45(2):64-71.
77. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155(7):914-920.
78. Daniel DG, Goldberg TE,Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry. 1996;153(3):417-419.
79. Emsley RA, Raniwalla J, Bailey PJ, Jones AM; PRIZE Study Group. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000;15(3):121-131.
80. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006;21(1):21-28.
81. Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry. 2011;72(2):194-204.
82. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 1993;29(2):309-314.
83. See RE, Fido AA, MauriceM, Ibrahim MM, Salama GM. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biol Psychiatry. 1999;45(12):1653-1656.
84. Sirota P, Pannet I, Koren A, Tchernichovsky E. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol. 2006;21(4):227-234.
85. Smith RC, InfanteM, Singh A, Khandat A. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol. 2001;4(3):239-250.
86. Wirshing DA, Marshall BD Jr, Green MF,Mintz J, Marder SR,WirshingWC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1999;156(9):1374-1379.
87. Conley RR, Kelly DL, NelsonMW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005;28(4): 163-168.
88. US Department of Health and Human Services Food and Drug Administration Office of Regulatory Affairs. Guidance for industry: guideline for the monitoring of clinical investigations. http://www .ahc.umn.edu/img/assets/19826/Clinical%20monitoring.pdf. Published January 1988. Accessed October 24, 2014.
89. Brunoni AR, Tadini L, Fregni F. Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. PLoS One. 2010;5(3):e9479.
90. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71(9):1115-1124.
91. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
92. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry. 2000;57 (10):987-994.
93. Agid O, Siu CO, Potkin SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry. 2013;170(11):1335-1344.
94. Leucht S, Arbter D, Engel RR, KisslingW, Davis JM. How effective are second-generation antipsychotic drugs? ameta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14 (4):429-447.
95. Rutherford BR, Pott E, Tandler JM,Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: ameta-analysis. JAMA Psychiatry. 2014;71(12):1409-1421.
96. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715-723.
97. Nyakyoma K, Morriss R. Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study. Psychopharmacol Bull. 2010;43(2):67-81.
98. Ciudad A, Haro JM, Alonso J, et al. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry. 2008;23(1):1-7.
99. Schneider C, Papachristou E,Wimberley T, et al. Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol. 2015;25(6):857-863.
100. Tiihonen J, Lonnqvist J,Wahlbeck K, et al. 11-Year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.
101. RingbackWeitoft G, Berglund M, Lindstrom EA, Nilsson M, Salmi P, Rosen M. Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden: a register-based study. Pharmacoepidemiol Drug Saf. 2014;23(3):290-298.
102. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192-208.
103. Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs. 2004;18(9):597-616.
104. Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry. 1999;156 (11):1744-1750.
105. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559-1573.
106. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205-1218.